Takashi Hojo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Takashi Hojo has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Takayuki Kinoshita
Department of Breast Surgery , National Cancer Center , Tokyo
6 shared publicationsTomoya Nagao
Department of Breast Oncology, National Cancer Center Hospital, Tokyo, Japan
3 shared publicationsHitoshi Tsuda
Department of Pathology, National Cancer Center Hospital, Tokyo, Japan
2 shared publicationsSadako Tanaka-Akashi
Department of Breast Oncology, National Cancer Center Hospital, Tokyo, Japan
2 shared publicationsAkashi-Tanaka Sadako
National Cancer Center Hospital
1 shared publication- Chikako Shimizu
Department of Breast and Medical University, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
1 shared publication
Latest Publications
- Open Access
- 5 August 2015
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 45 (10) , 983-986
Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204
This Phase III trial aims to determine the superiority of intensive follow-up to standard follow-up in terms of overall survival in high-risk breast cancer patients, who are expected to have recurrence rates of over 30% within 5 years after surgery. Eligible patients are randomized either to the intensive follow-up group or to the standard follow-up group; the former will undergo physical examination, bone scintigraphy, chest computed tomography, abdominal computed tomography, brain magnetic resonance imaging/computed tomography and frequent tumor marker evaluations, whereas the latter will undergo physical examination at the same frequency and tumor markers will be evaluated once a year. Mammography once a year is planned for both groups. The primary endpoint is overall survival. Patient accrual was started in November 2013. A total of 1700 patients will be enrolled for 3 years and followed up for 7 years after closure of accrual. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000012429.
- 5 August 2015
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 45 (10) , 983-986
Open AccessIntensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204
This Phase III trial aims to determine the superiority of intensive follow-up to standard follow-up in terms of overall survival in high-risk breast cancer patients, who are expected to have recurrence rates of over 30% within 5 years after surgery. Eligible patients are randomized either to the intensive follow-up group or to the standard follow-up group; the former will undergo physical examination, bone scintigraphy, chest computed tomography, abdominal computed tomography, brain magnetic resonance imaging/computed tomography and frequent tumor marker evaluations, whereas the latter will undergo physical examination at the same frequency and tumor markers will be evaluated once a year. Mammography once a year is planned for both groups. The primary endpoint is overall survival. Patient accrual was started in November 2013. A total of 1700 patients will be enrolled for 3 years and followed up for 7 years after closure of accrual. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000012429.
- Open Access
- 15 April 2013
- Published by Elsevier in The Breast
- Vol. 22 (3) , 263-267
Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy
- 15 April 2013
- Published by Elsevier in The Breast
- Vol. 22 (3) , 263-267
Open AccessUse of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy
- 8 November 2011
- Published by Hindawi Limited in The Breast Journal
- Vol. 18 (1) , 81-82
Primary Leiomyosarcoma of the Breast
- 8 November 2011
- Published by Hindawi Limited in The Breast Journal
- Vol. 18 (1) , 81-82
Primary Leiomyosarcoma of the Breast
- 14 June 2011
- Published by Springer Nature in Breast Cancer
- Vol. 21 (5) , 624-628
Sentinel lymph node biopsy in breast cancer patients with previous breast augmentation surgery
The number of breast augmentation surgeries (BAS) has increased. Therefore, the number of breast cancer patients with history of BAS has also increased. In this paper, we present two cases of sentinel lymph node biopsy (SLNB) in patients with previous BAS who were diagnosed with breast cancer. The patients were augmented using different approach; the first case was augmented through transaxillary incision, whereas the second case was augmented through periareolar incision. Lymphoscintigraphy (LPG) was performed on the patients 1 day prior to operation, enabling confirmation of lymphatic flow and SLN in both patients. SLNB was successfully performed in both cases. In one patient, SLNB was performed using indocyanine green (ICG) fluorescence and the Photodynamic Eye (PDE) system. Regardless of history of BAS, ICG and PDE system showed lymphatic flow and SLN in real time. LPG and ICG fluorescence were useful methods for SLN detection in patients with previous BAS, being able to confirm lymph flow before operation. Biopsy methods using LPG and PDE system were considered useful for difficult confirmation of lymph flow after breast augmentation. This is the first report of SLNB using ICG and PDE system for patients with previous BAS.
- 14 June 2011
- Published by Springer Nature in Breast Cancer
- Vol. 21 (5) , 624-628
Sentinel lymph node biopsy in breast cancer patients with previous breast augmentation surgery
The number of breast augmentation surgeries (BAS) has increased. Therefore, the number of breast cancer patients with history of BAS has also increased. In this paper, we present two cases of sentinel lymph node biopsy (SLNB) in patients with previous BAS who were diagnosed with breast cancer. The patients were augmented using different approach; the first case was augmented through transaxillary incision, whereas the second case was augmented through periareolar incision. Lymphoscintigraphy (LPG) was performed on the patients 1 day prior to operation, enabling confirmation of lymphatic flow and SLN in both patients. SLNB was successfully performed in both cases. In one patient, SLNB was performed using indocyanine green (ICG) fluorescence and the Photodynamic Eye (PDE) system. Regardless of history of BAS, ICG and PDE system showed lymphatic flow and SLN in real time. LPG and ICG fluorescence were useful methods for SLN detection in patients with previous BAS, being able to confirm lymph flow before operation. Biopsy methods using LPG and PDE system were considered useful for difficult confirmation of lymph flow after breast augmentation. This is the first report of SLNB using ICG and PDE system for patients with previous BAS.
- Open Access
- 1 June 2010
- Published by Elsevier in The Breast
- Vol. 19 (3) , 210-213
Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer
- 1 June 2010
- Published by Elsevier in The Breast
- Vol. 19 (3) , 210-213
Open AccessEvaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer
- 27 May 2008
- Published by Springer Nature in Breast Cancer
- Vol. 16 (1) , 68-71
Primary small cell carcinoma of the breast
Primary small cell carcinoma of the breast is a very rare disease, and only a few case reports have described small cell carcinoma of the breast that responds to chemotherapy. Here, we report a case of primary small cell carcinoma of the breast that was treated with surgery and chemotherapy for postoperative local recurrence in the chest wall and metastasis to the liver. The metastatic lesions showed a partial response (PR) to carboplatin and irinotecan, but did not respond to subsequent Taxotere and doxifluridine (5′-DFUR) treatment. We then treated the metastatic lesions with CBDCA and etoposide (VP-16), and were able to stop disease progression. Small cell carcinoma of the breast is as aggressive as its pulmonary counterpart. Therefore, the best therapy for primary small cell carcinoma of the breast may be surgery followed by adjuvant therapy similar to that recommended for small cell lung carcinoma.
- 27 May 2008
- Published by Springer Nature in Breast Cancer
- Vol. 16 (1) , 68-71
Primary small cell carcinoma of the breast
Primary small cell carcinoma of the breast is a very rare disease, and only a few case reports have described small cell carcinoma of the breast that responds to chemotherapy. Here, we report a case of primary small cell carcinoma of the breast that was treated with surgery and chemotherapy for postoperative local recurrence in the chest wall and metastasis to the liver. The metastatic lesions showed a partial response (PR) to carboplatin and irinotecan, but did not respond to subsequent Taxotere and doxifluridine (5′-DFUR) treatment. We then treated the metastatic lesions with CBDCA and etoposide (VP-16), and were able to stop disease progression. Small cell carcinoma of the breast is as aggressive as its pulmonary counterpart. Therefore, the best therapy for primary small cell carcinoma of the breast may be surgery followed by adjuvant therapy similar to that recommended for small cell lung carcinoma.